Literature DB >> 8900496

Role of 5-HT1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent findings from in vivo microdialysis studies.

A M Gardier1, I Malagié, A C Trillat, C Jacquot, F Artigas.   

Abstract

Although a new generation of selective serotonin reuptake inhibitors (SSRIs) has been introduced in therapeutics as antidepressant drugs, a two to four week lag period still occurs between starting treatment with SSRIs and the onset of therapeutic effects in man. In vivo cerebral microdialysis can be used to measure extracellular concentrations of serotonin (5-hydroxytryptamine, 5-HT), which reflect intrasynaptic events. With the coupling of this new experimental method to very sensitive analytical assays such as liquid chromatography with electrochemical detection, it has recently been possible to obtain two major arguments supporting the hypothesis that somatodendritic 5-HT1A autoreceptors situated in the raphe nuclei play an important role in the mechanism of action of SSRIs. First, in the rat, single administration of SSRIs at low doses comparable to those used therapeutically increases extracellular 5-HT concentrations in the vicinity of the cell body and the dendrites of serotoninergic neurones of the raphe nuclei. This effect is more marked than that observed in regions rich in nerve endings (frontal cortex). The magnitude of the activation of the serotoninergic neurotransmission depends on the brain area studied and the dose of the SSRIs administered to rats. This could be explained by simultaneous activation of somatodendritic 5-HT1A autoreceptors by endogenous 5-HT in the raphe nuclei, thereby limiting the corticofrontal effects of the antidepressant. Second, SSRIs cause a larger increase in extracellular 5-HT concentrations in the nerve endings when administered chronically: 5-HT autoreceptors may have gradually desensitized during the 2-4 weeks of treatment with SSRIs. Preliminary studies of patients with depression appear to confirm these experimental results, as co-administration of a 5-HT1A autoreceptor antagonist and a SSRI accelerated the onset of the antidepressant effect (< 1 week).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900496     DOI: 10.1111/j.1472-8206.1996.tb00145.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  41 in total

1.  Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study.

Authors:  I Malagié; A C Trillat; E Douvier; M C Anmella; M C Dessalles; C Jacquot; A M Gardier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-12       Impact factor: 3.000

Review 2.  Genetic approaches for understanding the role of serotonin receptors in mood and behavior.

Authors:  Zoe R Donaldson; Katherine M Nautiyal; Susanne E Ahmari; René Hen
Journal:  Curr Opin Neurobiol       Date:  2013-02-04       Impact factor: 6.627

3.  An altered spinal serotonergic system contributes to increased thermal nociception in an animal model of depression.

Authors:  Antonio Rodríguez-Gaztelumendi; María Luisa Rojo; Angel Pazos; Alvaro Díaz
Journal:  Exp Brain Res       Date:  2014-03-01       Impact factor: 1.972

4.  Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.

Authors:  Tracy M Felton; Tommy B Kang; Stephan Hjorth; Sidney B Auerbach
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-04       Impact factor: 3.000

Review 5.  Serotonin 1A and Serotonin 4 Receptors: Essential Mediators of the Neurogenic and Behavioral Actions of Antidepressants.

Authors:  Benjamin Adam Samuels; Indira Mendez-David; Charlène Faye; Sylvain André David; Kerri A Pierz; Alain M Gardier; René Hen; Denis J David
Journal:  Neuroscientist       Date:  2014-12-08       Impact factor: 7.519

6.  Lack of association between the serotonin transporter and serotonin 1A receptor: an in vivo PET imaging study in healthy adults.

Authors:  Michael Strupp-Levitsky; Jeffrey M Miller; Harry Rubin-Falcone; Francesca Zanderigo; Matthew S Milak; Gregory Sullivan; R Todd Ogden; Maria A Oquendo; Christine DeLorenzo; Norman Simpson; Ramin V Parsey; J John Mann
Journal:  Psychiatry Res Neuroimaging       Date:  2016-08-08       Impact factor: 2.376

7.  Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide.

Authors:  Swapnali Barde; Joelle Rüegg; Josée Prud'homme; Tomas J Ekström; Miklos Palkovits; Gustavo Turecki; Gyorgy Bagdy; Robert Ihnatko; Elvar Theodorsson; Gabriella Juhasz; Rochellys Diaz-Heijtz; Naguib Mechawar; Tomas G M Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-09       Impact factor: 11.205

8.  Strategy to Accelerate or Augment the Antidepressant Response and for An Early Onset of SSRI Activity. Adjunctive Amisulpride to Fluvoxamine in Major Depressive Disorder.

Authors:  Maria Carolina Hardoy; Mauro Giovanni Carta
Journal:  Clin Pract Epidemiol Ment Health       Date:  2010-01-27

Review 9.  Imaging the serotonin 1A receptor using [11C]WAY100635 in healthy controls and major depression.

Authors:  Natalie Hesselgrave; Ramin V Parsey
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

10.  Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors.

Authors:  I Ceglia; S Acconcia; C Fracasso; M Colovic; S Caccia; R W Invernizzi
Journal:  Br J Pharmacol       Date:  2004-05-17       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.